Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2023
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024